NVCR

10.55

2.68% -0.29

Dopo l'orario di chiusura: 10.51 -0.04 -0.38%

Novocure Ltd (NVCR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NVCR Giù? Forum Previsione

Precedente Chiudi:

$10.84

Aprire:

$10.52

Volume 24 ore:

1.13M

Relative Volume:

0.64

Capitalizzazione di mercato:

$1.20B

Reddito:

$655.35M

Utile/perdita netta:

$-136.23M

Rapporto P/E:

-8.6313

EPS:

-1.2223

Flusso di cassa netto:

$-75.68M

1 W Prestazione:

-10.29%

1M Prestazione:

-21.97%

6M Prestazione:

-24.91%

1 anno Prestazione:

-41.19%

Intervallo 1D:

$10.30

$10.87

Intervallo di 1 settimana:

$10.25

$11.62

Portata 52W:

$9.82

$20.06

Novocure Ltd Stock (NVCR) Company Profile

Nome

Novocure Ltd

Settore

Healthcare (1118)

Industria

Medical Devices (144)

Telefono

44 (0)15 3475 6700

Indirizzo

NO. 4 THE FORUM, ST. HELIER

Dipendente

1,605

Cinguettio

@novocure

Prossima data di guadagno

2026-04-23

Ultimi documenti SEC

NVCR's Discussions on Twitter

Compare NVCR vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NVCR Novocure Ltd	10.55	1.20B	655.35M	-136.23M	-75.68M	-1.2223
ABT Abbott Laboratories	102.87	178.75B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	331.54	126.97B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	86.63	111.22B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	62.82	93.36B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	81.05	46.73B	6.07B	1.06B	1.34B	1.8063

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-07-08	Iniziato	Ladenburg Thalmann	Buy
2024-12-02	Aggiornamento	Evercore ISI	In-line → Outperform
2024-10-16	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-11-20	Ripresa	JP Morgan	Neutral
2023-08-28	Downgrade	H.C. Wainwright	Buy → Neutral
2023-08-08	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-08-04	Iniziato	SVB Securities	Outperform
2023-07-31	Aggiornamento	Evercore ISI	Underperform → In-line
2023-06-07	Aggiornamento	Wedbush	Underperform → Neutral
2023-05-16	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-17	Downgrade	JP Morgan	Neutral → Underweight
2023-01-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-01-05	Reiterato	H.C. Wainwright	Buy
2022-11-29	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-10-24	Downgrade	Piper Sandler	Overweight → Neutral
2022-07-05	Downgrade	Evercore ISI	In-line → Underperform
2022-05-16	Iniziato	H.C. Wainwright	Buy
2022-02-08	Iniziato	Loop Capital	Buy
2022-02-02	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-20	Aggiornamento	Truist	Hold → Buy
2022-01-03	Aggiornamento	Evercore ISI	Underperform → In-line
2021-07-01	Downgrade	Mizuho	Buy → Neutral
2021-04-14	Downgrade	Wedbush	Neutral → Underperform
2021-01-25	Reiterato	Piper Sandler	Overweight
2020-09-23	Iniziato	Northland Capital	Outperform
2020-09-18	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-09-17	Downgrade	Truist	Buy → Hold
2020-06-01	Ripresa	Oppenheimer	Perform
2020-05-01	Downgrade	Oppenheimer	Outperform → Perform
2020-04-09	Downgrade	Evercore ISI	In-line → Underperform
2020-03-05	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-01-02	Downgrade	Evercore ISI	Outperform → In-line
2019-07-29	Aggiornamento	SunTrust	Hold → Buy
2019-07-26	Downgrade	JP Morgan	Overweight → Neutral
2019-07-26	Downgrade	Wedbush	Outperform → Neutral
2019-03-20	Iniziato	SunTrust	Hold
2018-11-02	Downgrade	Wells Fargo	Outperform → Market Perform
2018-07-16	Iniziato	Evercore ISI	Outperform
2018-04-18	Reiterato	Mizuho	Buy
2018-02-23	Reiterato	Mizuho	Buy
2017-05-24	Aggiornamento	Wells Fargo	Market Perform → Outperform
2016-07-29	Reiterato	Wedbush	Outperform
2016-01-19	Iniziato	Barclays	Underweight
2015-12-02	Iniziato	Deutsche Bank	Hold

Mostra tutto

Novocure Ltd Borsa (NVCR) Ultime notizie

Apr 04, 2026

NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer - Sahm

Apr 04, 2026

JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR - MarketBeat

Apr 04, 2026

Apr 03, 2026

NovoCure Ltd (038.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore

Apr 03, 2026

SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR - MarketBeat

Apr 03, 2026

Apr 02, 2026

NovoCure Limited (NVCR) stock price, news, quote and history - Yahoo Finance UK

Apr 02, 2026

NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer - MSN

Apr 02, 2026

NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed? - finance.yahoo.com

Apr 02, 2026

Apr 01, 2026

NovoCure Ltd to release first quarter 2026 financial results on April 30 - Traders Union

Apr 01, 2026

Novocure to Report First Quarter 2026 Financial Results - finance.yahoo.com

Apr 01, 2026

Mar 31, 2026

NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Mar 31, 2026

Mar 30, 2026

NovoCure’s EF-32 Optune® Trial Reaches Completion, Setting Up a Key Catalyst for NVCR Investors - TipRanks

Mar 30, 2026

Mar 29, 2026

A Look At NovoCure (NVCR) Valuation After Extended Share Price Weakness - simplywall.st

Mar 29, 2026

Mar 27, 2026

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $49 - Moomoo

Mar 27, 2026

Mar 26, 2026